These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. PEGylation Prolongs the Half-Life of Equine Anti-SARS-CoV-2 Specific F(ab') Xu M; Bi J; Liang B; Wang X; Mo R; Feng N; Yan F; Wang T; Yang S; Zhao Y; Xia X Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834803 [TBL] [Abstract][Full Text] [Related]
5. Therapeutic equine hyperimmune antibodies with high and broad-spectrum neutralizing activity protect rodents against SARS-CoV-2 infection. Li E; Han Q; Bi J; Wei S; Wang S; Zhang Y; Liu J; Feng N; Wang T; Wu J; Yang S; Zhao Y; Liu B; Yan F; Xia X Front Immunol; 2023; 14():1066730. PubMed ID: 36875106 [TBL] [Abstract][Full Text] [Related]
6. Passive immunotherapy for Middle East Respiratory Syndrome coronavirus infection with equine immunoglobulin or immunoglobulin fragments in a mouse model. Zhao Y; Wang C; Qiu B; Li C; Wang H; Jin H; Gai W; Zheng X; Wang T; Sun W; Yan F; Gao Y; Wang Q; Yan J; Chen L; Perlman S; Zhong N; Zhao J; Yang S; Xia X Antiviral Res; 2017 Jan; 137():125-130. PubMed ID: 27890674 [TBL] [Abstract][Full Text] [Related]
7. Evaluation of the safety, immunogenicity and pharmacokinetics of equine anti-SARS-CoV F(ab')(2) in macaque. Xu Y; Jia Z; Zhou L; Wang L; Li J; Liang Y; Zhao T; Ni B; Wu Y Int Immunopharmacol; 2007 Dec; 7(13):1834-40. PubMed ID: 17996696 [TBL] [Abstract][Full Text] [Related]
8. Protection from infection with severe acute respiratory syndrome coronavirus in a Chinese hamster model by equine neutralizing F(ab')2. Luo D; Ni B; Zhao G; Jia Z; Zhou L; Pacal M; Zhang L; Zhang S; Xing L; Lin Z; Wang L; Li J; Liang Y; Shi X; Zhao T; Zou L; Wu Y; Wang X Viral Immunol; 2007 Sep; 20(3):495-502. PubMed ID: 17931120 [TBL] [Abstract][Full Text] [Related]
10. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History. Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S Front Immunol; 2021; 12():793191. PubMed ID: 34975897 [TBL] [Abstract][Full Text] [Related]
11. An Assessment of Serological Assays for SARS-CoV-2 as Surrogates for Authentic Virus Neutralization. Wohlgemuth N; Whitt K; Cherry S; Kirkpatrick Roubidoux E; Lin CY; Allison KJ; Gowen A; Freiden P; Allen EK; ; Gaur AH; Estepp JH; Tang L; Mori T; Hijano DR; Hakim H; McGargill MA; Krammer F; Whitt MA; Wolf J; Thomas PG; Schultz-Cherry S Microbiol Spectr; 2021 Oct; 9(2):e0105921. PubMed ID: 34704832 [TBL] [Abstract][Full Text] [Related]
12. SARS Coronavirus-2 Microneutralisation and Commercial Serological Assays Correlated Closely for Some but Not All Enzyme Immunoassays. Walker GJ; Naing Z; Ospina Stella A; Yeang M; Caguicla J; Ramachandran V; Isaacs SR; Agapiou D; Bull RA; Stelzer-Braid S; Daly J; Gosbell IB; Hoad VC; Irving DO; Pink JM; Turville S; Kelleher AD; Rawlinson WD Viruses; 2021 Feb; 13(2):. PubMed ID: 33557418 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of a multiplexed coronavirus antigen array for detection of SARS-CoV-2 specific IgG in COVID-19 convalescent plasma. Huey L; Andersen G; Merkel PA; Morrison TE; McCarthy M; DomBourian MG; Annen K; Dawson ED; Rowlen KL; Knight V J Immunol Methods; 2021 Oct; 497():113104. PubMed ID: 34303688 [TBL] [Abstract][Full Text] [Related]
14. A qualitative IgG ELISA for detection of SARS-CoV-2-specific antibodies in Syrian hamster serum samples. Shete A; Mohandas S; Jain R; Yadav PD STAR Protoc; 2021 Jun; 2(2):100573. PubMed ID: 33997801 [TBL] [Abstract][Full Text] [Related]
15. Mapping SARS-CoV-2 Antibody Epitopes in COVID-19 Patients with a Multi-Coronavirus Protein Microarray. Camerini D; Randall AZ; Trappl-Kimmons K; Oberai A; Hung C; Edgar J; Shandling A; Huynh V; Teng AA; Hermanson G; Pablo JV; Stumpf MM; Lester SN; Harcourt J; Tamin A; Rasheed M; Thornburg NJ; Satheshkumar PS; Liang X; Kennedy RB; Yee A; Townsend M; Campo JJ Microbiol Spectr; 2021 Oct; 9(2):e0141621. PubMed ID: 34704808 [TBL] [Abstract][Full Text] [Related]
16. Passive immunotherapy for influenza A H5N1 virus infection with equine hyperimmune globulin F(ab')2 in mice. Lu J; Guo Z; Pan X; Wang G; Zhang D; Li Y; Tan B; Ouyang L; Yu X Respir Res; 2006 Mar; 7(1):43. PubMed ID: 16553963 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of Three Quantitative Anti-SARS-CoV-2 Antibody Immunoassays. Chapuy-Regaud S; Miédougé M; Abravanel F; Da Silva I; Porcheron M; Fillaux J; Diméglio C; Izopet J Microbiol Spectr; 2021 Dec; 9(3):e0137621. PubMed ID: 34937195 [TBL] [Abstract][Full Text] [Related]
18. Cross clade prophylactic and therapeutic efficacy of polyvalent equine immunoglobulin F(ab')2 against highly pathogenic avian influenza H5N1 in mice. Zhao Z; Yan F; Chen Z; Luo D; Duan Y; Yang P; Li Z; Peng D; Liu X; Wang X Int Immunopharmacol; 2011 Dec; 11(12):2000-6. PubMed ID: 21906698 [TBL] [Abstract][Full Text] [Related]
19. Refinement of an ovine-based immunoglobulin therapy against SARS-CoV-2, with comparison of whole IgG versus F(ab') Findlay-Wilson S; Easterbrook L; Smith S; Pope N; Aldridge M; Humphries G; Schuhmann H; Ngabo D; Rayner E; Otter A; Coleman T; Hicks B; Halkerston R; Apostolakis K; Taylor S; Fotheringham S; Horton A; CanoCejas I; Wand M; Tree JA; Sutton M; Graham V; Hewson R; Dowall S Sci Rep; 2023 Aug; 13(1):13912. PubMed ID: 37626085 [TBL] [Abstract][Full Text] [Related]
20. Neutralizing Antibody Responses to SARS-CoV-2 in Recovered COVID-19 Patients Are Variable and Correlate With Disease Severity and Receptor-Binding Domain Recognition. Maciola AK; La Raja M; Pacenti M; Salata C; De Silvestro G; Rosato A; Pasqual G Front Immunol; 2022; 13():830710. PubMed ID: 35173741 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]